Orlistat Reduces Uric Acid in Overweight/Obese Patients With Hyperuricemia

Summary

To clarify the uric acid-lowering efficacy of orlistat in overweight/obese patients with hyperuricemia, and to evaluate the safety of orlistat treatment

Timeline

Start

2022-08-26

Primary completion

2023-12-01

Completion

2023-12-01

Outcome

Mixed primary results

paper There was no significant difference in SUA level between the two groups. PMID 38468241 ↗

paper The weight loss in the orlistat group was significantly greater than that in the control group (P < 0.05). PMID 38468241 ↗

paper Orlistat reduced the proportion of patients with gout flares (log-rank P = 0.023, hazard ratio = 0.31, 95% confidence interval 0.11-0.85). PMID 38468241 ↗

Publications

• Liu S, Lin X, Tao M, Chen Q, Sun H, Han Y, Yang S, Gao Y, Qu S, Chen H. Efficacy and safety of orlistat in male patients with overweight/obesity and hyperuricemia: results of a randomized, double-blind, placebo-controlled trial. Lipids Health Dis. 2024 Mar 11;23(1):77. doi: 10.1186/s12944-024-02047-7.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Orlistat	Small molecule	0.12 g	Oral

Indications

No indication recorded.